GlassScriptPhysician profile
Mohammad S Alnabulsi
NPI 1669953212
$5,170.86
in general payments reported to CMS, 2019-2025
20 companies · $4,610 in 2025
The $4,610 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $561 · 2025: $4,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,342 · Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,342.05 |
| Food and Beverage | $1,328.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,859.04 | 2025 | |
| Glaxosmithkline, LLC. | $308.88 | 2024-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $296.70 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $133.24 | 2024-2025 | Dupixent |
| Insmed, INC. | $107.70 | 2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $90.66 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.77 | 2024-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $39.87 | 2025 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $35.84 | 2024 | Glassia |
| Mallinckrodt Hospital Products INC. | $26.42 | 2025 | Acthar |
| Ethicon INC. | $25.45 | 2024 | Monarch Platform |
| Boston Scientific Corporation | $24.42 | 2025 | Cds - Mct/Cem Monitoring |
| Resmed Corp | $22.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.50 | 2025 | |
| Amgen INC. | $19.75 | 2025 | Tezspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18.16 | 2025 | Opsynvi, Uptravi |
| Viatris Specialty LLC | $18.09 | 2025 | Yupelri |
| Gilead Sciences, INC. | $17.51 | 2024 | |
| Genentech USA, INC. | $16.02 | 2025 | Xolair |
| Baxter Healthcare | $15.84 | 2024 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alnabulsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.